DexCom, Inc. (DXCM) Stake Lowered by Savant Capital LLC
Savant Capital LLC reduced its holdings in DexCom, Inc. (NASDAQ:DXCM) by 14.9% during the 4th quarter, HoldingsChannel reports. The fund owned 31,849 shares of the medical device company’s stock after selling 5,564 shares during the quarter. Savant Capital LLC’s holdings in DexCom were worth $3,816,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc lifted its holdings in DexCom by 11.5% during the 3rd quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock worth $1,136,147,000 after buying an additional 816,247 shares in the last quarter. Capital International Investors bought a new stake in shares of DexCom during the 3rd quarter valued at $475,951,000. Columbus Circle Investors raised its position in shares of DexCom by 32.3% during the 3rd quarter. Columbus Circle Investors now owns 704,747 shares of the medical device company’s stock valued at $100,807,000 after acquiring an additional 172,258 shares during the last quarter. Gilder Gagnon Howe & Co. LLC raised its position in shares of DexCom by 17.4% during the 3rd quarter. Gilder Gagnon Howe & Co. LLC now owns 700,487 shares of the medical device company’s stock valued at $100,198,000 after acquiring an additional 103,757 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of DexCom by 49.1% during the 3rd quarter. Renaissance Technologies LLC now owns 583,059 shares of the medical device company’s stock valued at $83,401,000 after acquiring an additional 191,916 shares during the last quarter.
Several analysts have commented on the stock. UBS Group upped their target price on shares of DexCom from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, January 8th. Oppenheimer set a $150.00 target price on shares of DexCom and gave the company a “buy” rating in a research report on Thursday, December 6th. Stephens upped their target price on shares of DexCom from $170.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday, November 7th. Goldman Sachs Group upgraded shares of DexCom from a “sell” rating to a “neutral” rating and set a $125.00 target price for the company in a research report on Friday, October 19th. Finally, BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Friday, December 28th. Seven analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. DexCom currently has an average rating of “Buy” and a consensus target price of $143.53.
In other DexCom news, CEO Kevin R. Sayer sold 11,162 shares of the stock in a transaction dated Monday, December 10th. The stock was sold at an average price of $121.67, for a total transaction of $1,358,080.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Steven Robert Pacelli sold 3,114 shares of the stock in a transaction dated Wednesday, January 23rd. The stock was sold at an average price of $149.74, for a total value of $466,290.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 49,057 shares of company stock valued at $6,453,129. 1.80% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) Stake Lowered by Savant Capital LLC” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/dexcom-inc-dxcm-stake-lowered-by-savant-capital-llc/2812939.html.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Read More: Dividend Stocks – Are They Right For You?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.